SlideShare a Scribd company logo
1 of 5
Download to read offline
P-OM3
P-OM3
PR Kowey (Lankenau Institute for medical Research, Wynnewood, PA)
American Heart Association 2010 Scientific Sessions



• One of the largest studies to examine the effect of omega-3 polyunsaturated
  fatty acids (PUFA) on AF
• Population and treatment:
    663 outpatients with documented symptomatic paroxysmal or persistent AF
    (n=542 and n=121, respectively) without significant structural heart disease
    and initially in sinus rhythm
    Randomized to receive placebo or the prescription omega-3 PUFA capsules
    (fish oil) at 8 g/day for the first seven days followed by 4 g/day for total of 24
    weeks
• Primary outcome:
    First recurrence of symptomatic AF or atrial flutter
P-OM3: Results

• Fish oil did not show an effect on the primary end point but there were trends
 toward a reduction in average ventricular rate during the first AF recurrence and a
 reduction in triglyceride levels at week 24

Rate of primary end point by AF type and treatment group and HR for
active therapy vs placebo

Patient group                Placebo (%)     Omega-3 PUFA (%)   HR (95% CI)        p

Paroxysmal AF* (n=542)       48              52                 1.15 (0.90–1.46)   0.26

Persistent AF (n=121)        33              50                 1.64 (0.92–2.92)   0.09

Any AF (all patients)        46              52                 1.22 (0.98–1.52)   0.08
P-OM3: Commentary*

"There is no precedent for a drug that didn't work in the population we studied
working in other populations, in atrial fibrillation. The fact that this drug failed in this
population, in my mind, makes it highly unlikely that you'll see efficacy in other
groups."
                                                                        - Dr Peter R Kowey


"There may be a lesson. . . . Maybe we have to test [supplements] just like we do
drugs."

                                                                                        - Dr Robert Califf




*All comments from Omega-3 PUFA caps don't suppress paroxysmal AF in randomized trial
 (http://www.theheart.org/article/1148957.do)
Become a member of http://www.theheart.org
    Become a fan on Facebook: http://www.facebook.com/theheartorg
          Follow us on Twitter: http://www.twitter.com/theheartorg

theheart.org is the leading online source of independent cardiology news.
We are the top provider of news and opinions for over 100 000 physicians.

More Related Content

Similar to P-OM3 trial - Summary & Results

Presentation - Omega-3 PUFAs and Metabolic Syndrome
Presentation - Omega-3 PUFAs and Metabolic SyndromePresentation - Omega-3 PUFAs and Metabolic Syndrome
Presentation - Omega-3 PUFAs and Metabolic Syndrome
Josh Nooner
 
Death by Neurological Criteria and Organ Donation: Bill Knight
Death by Neurological Criteria and Organ Donation: Bill KnightDeath by Neurological Criteria and Organ Donation: Bill Knight
Death by Neurological Criteria and Organ Donation: Bill Knight
SMACC Conference
 
Omega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
Omega-3 Polyunsaturated Fatty Acids and Metabolic SyndromeOmega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
Omega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
Josh Nooner
 
Sarathy Danyas PNS FINAL
Sarathy Danyas PNS FINALSarathy Danyas PNS FINAL
Sarathy Danyas PNS FINAL
danyas sarathy
 
Danielle.Degroot.Case Study Pp
Danielle.Degroot.Case Study PpDanielle.Degroot.Case Study Pp
Danielle.Degroot.Case Study Pp
DanielleDDI
 
Vets 238 Intro Preanesthesia Final Draft
Vets 238   Intro Preanesthesia Final DraftVets 238   Intro Preanesthesia Final Draft
Vets 238 Intro Preanesthesia Final Draft
meckelbt
 
Creatine Presentation Final
Creatine Presentation FinalCreatine Presentation Final
Creatine Presentation Final
AndrewRosenthal
 

Similar to P-OM3 trial - Summary & Results (20)

Presentation - Omega-3 PUFAs and Metabolic Syndrome
Presentation - Omega-3 PUFAs and Metabolic SyndromePresentation - Omega-3 PUFAs and Metabolic Syndrome
Presentation - Omega-3 PUFAs and Metabolic Syndrome
 
Wilmore Labs
Wilmore LabsWilmore Labs
Wilmore Labs
 
Dementias advances in treatment
Dementias advances in treatmentDementias advances in treatment
Dementias advances in treatment
 
Best practices
Best practicesBest practices
Best practices
 
Omega
OmegaOmega
Omega
 
Death by Neurological Criteria and Organ Donation: Bill Knight
Death by Neurological Criteria and Organ Donation: Bill KnightDeath by Neurological Criteria and Organ Donation: Bill Knight
Death by Neurological Criteria and Organ Donation: Bill Knight
 
Family Physician's Approach to Lower Urinary Tract Symptoms in Males
Family Physician's Approach to Lower Urinary Tract Symptoms in MalesFamily Physician's Approach to Lower Urinary Tract Symptoms in Males
Family Physician's Approach to Lower Urinary Tract Symptoms in Males
 
Family Physician's Approach to Lower Urinary Tract Symptoms
Family Physician's Approach to Lower Urinary Tract SymptomsFamily Physician's Approach to Lower Urinary Tract Symptoms
Family Physician's Approach to Lower Urinary Tract Symptoms
 
Obstructive sleep apnea
Obstructive sleep apneaObstructive sleep apnea
Obstructive sleep apnea
 
Value of the Mediterranean diet
Value of the Mediterranean dietValue of the Mediterranean diet
Value of the Mediterranean diet
 
Omega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
Omega-3 Polyunsaturated Fatty Acids and Metabolic SyndromeOmega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
Omega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
 
Sarathy Danyas PNS FINAL
Sarathy Danyas PNS FINALSarathy Danyas PNS FINAL
Sarathy Danyas PNS FINAL
 
Bph case studies 10.7.11 dr lei
Bph case studies 10.7.11 dr leiBph case studies 10.7.11 dr lei
Bph case studies 10.7.11 dr lei
 
Nervous system
Nervous system Nervous system
Nervous system
 
Nuevas alternativas en el manejo de los miomas uterinos.
Nuevas alternativas en el manejo de los miomas uterinos.Nuevas alternativas en el manejo de los miomas uterinos.
Nuevas alternativas en el manejo de los miomas uterinos.
 
Danielle.Degroot.Case Study Pp
Danielle.Degroot.Case Study PpDanielle.Degroot.Case Study Pp
Danielle.Degroot.Case Study Pp
 
Nafld management -_challenges_involved
Nafld management -_challenges_involvedNafld management -_challenges_involved
Nafld management -_challenges_involved
 
Vets 238 Intro Preanesthesia Final Draft
Vets 238   Intro Preanesthesia Final DraftVets 238   Intro Preanesthesia Final Draft
Vets 238 Intro Preanesthesia Final Draft
 
Creatine Presentation Final
Creatine Presentation FinalCreatine Presentation Final
Creatine Presentation Final
 
Coversyl plus HD 2016
Coversyl plus HD 2016Coversyl plus HD 2016
Coversyl plus HD 2016
 

More from theheart.org

More from theheart.org (20)

TCT 2012 research highlights: A slideshow presentation
TCT 2012 research highlights: A slideshow presentationTCT 2012 research highlights: A slideshow presentation
TCT 2012 research highlights: A slideshow presentation
 
ESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentationESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentation
 
AHA 2012 Research Highlights
AHA 2012 Research HighlightsAHA 2012 Research Highlights
AHA 2012 Research Highlights
 
AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation
 
TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation
 
ESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentationESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentation
 
CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results
 
ONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global EndpointONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global Endpoint
 
OASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACCOASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACC
 
IDEAL trial - Summary & Results
IDEAL trial - Summary & ResultsIDEAL trial - Summary & Results
IDEAL trial - Summary & Results
 
PURE trial - Summary & Results
PURE trial - Summary & ResultsPURE trial - Summary & Results
PURE trial - Summary & Results
 
ACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & ResultsACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & Results
 
RIVAL trial - Summary & Results
RIVAL trial - Summary & ResultsRIVAL trial - Summary & Results
RIVAL trial - Summary & Results
 
ACT trial - Summary & Results
ACT trial - Summary & ResultsACT trial - Summary & Results
ACT trial - Summary & Results
 
TRITON-TIMI 38 trial - Summary & Results
TRITON-TIMI 38 trial - Summary & ResultsTRITON-TIMI 38 trial - Summary & Results
TRITON-TIMI 38 trial - Summary & Results
 
SHIFT trial - Summary & Results
SHIFT trial - Summary & ResultsSHIFT trial - Summary & Results
SHIFT trial - Summary & Results
 
PROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & ResultsPROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & Results
 
PRELUDE trial - Summary & Results
PRELUDE trial - Summary & ResultsPRELUDE trial - Summary & Results
PRELUDE trial - Summary & Results
 
ALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & ResultsALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & Results
 
PRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & ResultsPRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & Results
 

Recently uploaded

Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
MedicoseAcademics
 

Recently uploaded (20)

Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadHemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
Denture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDenture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of action
 
PREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptxPREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptx
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic trauma
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial health
 
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHYTUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
 

P-OM3 trial - Summary & Results

  • 2. P-OM3 PR Kowey (Lankenau Institute for medical Research, Wynnewood, PA) American Heart Association 2010 Scientific Sessions • One of the largest studies to examine the effect of omega-3 polyunsaturated fatty acids (PUFA) on AF • Population and treatment: 663 outpatients with documented symptomatic paroxysmal or persistent AF (n=542 and n=121, respectively) without significant structural heart disease and initially in sinus rhythm Randomized to receive placebo or the prescription omega-3 PUFA capsules (fish oil) at 8 g/day for the first seven days followed by 4 g/day for total of 24 weeks • Primary outcome: First recurrence of symptomatic AF or atrial flutter
  • 3. P-OM3: Results • Fish oil did not show an effect on the primary end point but there were trends toward a reduction in average ventricular rate during the first AF recurrence and a reduction in triglyceride levels at week 24 Rate of primary end point by AF type and treatment group and HR for active therapy vs placebo Patient group Placebo (%) Omega-3 PUFA (%) HR (95% CI) p Paroxysmal AF* (n=542) 48 52 1.15 (0.90–1.46) 0.26 Persistent AF (n=121) 33 50 1.64 (0.92–2.92) 0.09 Any AF (all patients) 46 52 1.22 (0.98–1.52) 0.08
  • 4. P-OM3: Commentary* "There is no precedent for a drug that didn't work in the population we studied working in other populations, in atrial fibrillation. The fact that this drug failed in this population, in my mind, makes it highly unlikely that you'll see efficacy in other groups." - Dr Peter R Kowey "There may be a lesson. . . . Maybe we have to test [supplements] just like we do drugs." - Dr Robert Califf *All comments from Omega-3 PUFA caps don't suppress paroxysmal AF in randomized trial (http://www.theheart.org/article/1148957.do)
  • 5. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorg theheart.org is the leading online source of independent cardiology news. We are the top provider of news and opinions for over 100 000 physicians.